SYNAPSE Microcurrent has been appointed onto a national framework agreement for innovative wound healing technologies. NHS Shared Business Services (NHS SBS) has awarded the company a two-year agreement after a competition involving more than 50 companies. In total, just four technologies were chosen. Accel-Heal builds on the long-established link between electrical current and the body's healing mechanisms. A compact device fitted with Synapse's patented micro-current technology, it is generally used as an adjunct treatment to compression bandages to significantly accelerate healing and improve patient comfort. John Gildersleeve, chief executive of Synapse, said: "The acceptance of Accel-Heal onto the framework agreement is an endorsement, not only of this remarkable product, but of the conviction we have demonstrated over a number of years in researching, developing and bringing to market a revolutionary new approach to the treatment of wounds; one that will not only have a dramatic effect on the quality of life for long-suffering chronic would patients, but also on costs."
Synapse wins place on wound healing framework
You may also like
Trending Articles
You may also like
Medical Devices
GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions
The anticipated acquisition aligns with GE HealthCare’s precision care strategy with the goal of strengthening the company’s portfolio of offerings in neurological care and its quantitative analysis of brain MRI